Fauci
Anthony Fauci, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20110086024 | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN - Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. | 04-14-2011 |
Anthony S. Fauci, Washington, DC US
Patent application number | Description | Published |
---|---|---|
20090285815 | IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION - Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. | 11-19-2009 |
Francesco Fauci, Palermo-Pa IT
Patent application number | Description | Published |
---|---|---|
20090274349 | METHOD FOR PROCESSING BIOMEDICAL IMAGES - The present invention relates to a method for highlight and to diagnose regions of interest in biomedical radiographic images, useful in the context of a CAD tool processing operating as second reader during the normal clinical and screening routine, so reducing the costs of management of the “double reading” procedure. | 11-05-2009 |
Mark A. Fauci, Patchogue, NY US
Patent application number | Description | Published |
---|---|---|
20130096817 | TRACKING ACTIVITY, VELOCITY, AND HEADING USING SENSORS IN MOBILE DEVICES OR OTHER SYSTEMS - Embodiments of the invention provide systems and methods for tracking a mobile device using sensors within the device and without using external signals to determine location, velocity, or heading. According to one embodiment, locating and tracking a mobile device can comprise reading sensor data from each of a plurality of sensors within the mobile device. The sensors can provide the sensor data without relying on a signal from a device external to the mobile device. For example, the plurality of sensors can comprise a compass, a gyroscope, and an accelerometer. Motion, velocity, and heading of the mobile device can be determined based on the sensor data. | 04-18-2013 |
20130261794 | METHODS AND SYSTEMS TO SECURE CONTROL AND ENHANCE MEDICATION ADHERENCE - Embodiments of the invention provide systems and methods to provide safe, secure and accurate point-to-point delivery of prescription and non-prescription drugs in the long-term home care or ambulatory care environment. More specifically, embodiments of the present invention provide for a low-cost, easy-to-use system comprised of a secure drug dispensing unit and medication enclosure combined with wireless connectivity and software based on smart mobile phone technology. Such systems and methods, referred to herein as a Secure, Control, and Enhance Medication Adherence (SCEMA) system, can mitigate the aforementioned risks associated with the use of prescription and non-prescription drugs. These risks can be significantly reduced for the elderly in the homecare environment, as well as the general public, without disrupting, or a significantly increasing the cost, to the existing prescription and non-prescription drug distribution infrastructure. In addition, the SCEMA system can provide a powerful platform for drug research. | 10-03-2013 |